Please login to the form below

Not currently logged in
Email:
Password:

Roche’s Torsten Hoffmann to join Zealand Pharma

Joins the Danish biotech as chief scientific officer

Zealand Pharma Torsten Hoffmann Dr Torsten Hoffmann has left his senior role at pharma company Roche to join the Danish biotech Zealand Pharma as chief scientific officer.

Dr Hoffmann (pictured) was head of head of discovery chemistry, pharma research, at Roche – a role he'd held since 2005.

He initially joined the company in 1997 as a laboratory head before working his way up the ranks in early-stage science, and was responsible for the identification of more than 25 drug candidates that entered clinical development.

In his new role at Zealand, Dr Hoffmann joins a more compact company focused on the discovery of drugs in cardio-metabolic diseases, diabetes and obesity.

Its lead product is the GLP-1 agonist lixisenatide, which is licensed to Sanofi who markets it as Lyxumia for the treatment of type 2 diabetes.

"These are exciting times for the company following the launch of its first discovered medicine,” commented Dr Hoffmann.

As chief scientific officer, Dr Hoffmann will be expected to further drive innovation and strengthen Zealn's research efforts, which includes collaborations with Boehringer Ingelheim and Lilly.

“Torsten is known for being a strong and collaborative leader and his impressive and impactful scientific record plus wealth of sector experience and innovative ideas will be extremely valuable to our company,” said Zealand's CEO David Solomon.

“I am confident that under his leadership, we can drive Zealand's R&D activities further towards tomorrow's breakthrough peptide therapeutics.”

4th September 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics